# SOLVE Chemistry

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solve-chemistry

- Industry: Chemicals
- Headquarters: London, UK
- Website: www.solvechemistry.com
- Total disclosed funding: $5.4M
- Latest round: Seed (Jan 27, 2026)
- Investors on record: 4

## About

Based in London, UK, SOLVE Chemistry specializes in automating chemical processes for pharmaceutical and agrochemical companies, enhancing efficiency and providing data-driven insights for organic synthesis developments. SOLVE Chemistry, founded in 2024 by Dr Linden Schrecker and Dr Jose Pablo Folch, operates out of London, UK, focusing on providing innovative solutions for chemical processes. Dr Linden Schrecker is the current CEO. In August 2025, SOLVE Chemistry raised GBP 3.99 million in seed funding led by new investor XTX Ventures, with participation from other new investors SuperSeed, and Endgame Capital. Returning investor Creator Fund and Individual investors also participated in the round. SOLVE Chemistry specializes in providing innovative solutions that enhance the efficiency of chemical processes for pharmaceutical and agrochemical companies engaged in the development of organic synthesis. Their core offerings include an automated lab that collects high-quality quantitative kinetic data and generates machine-actionable datasets that adhere to FAIR principles. These products enable clients to obtain rapid insights into reaction conditions, solvent choices, and kinetic models, significantly reducing the time required for process development—from an average of three months to just two weeks. Their technology is designed to serve a diverse clientele, including research and development teams in various geographical markets such as North America, Europe, and parts of Asia, focusing on the pharmaceutical and agrochemical sectors. By utilizing advanced machine learning models and micro-kinetic modeling, SOLVE Chemistry empowers companies to make data-driven decisions that optimize yields while prioritizing cost and sustainability.The revenue model for SOLVE Chemistry revolves around providing comprehensive data-driven insights and solutions to its business clients through a subscription-based service structure. Clients engage with the company's offerings under various arrangements, including direct access to proprietary models and analytics tools that streamline their process development efforts. The transactions typically involve long-term partnerships, where clients subscribe to access specific data services, facilitating continuous integration of SOLVE's insights into their workflows. Pricing structures for these services are tailored according to the specific needs of each client, factoring in the scale and complexity of their projects. SOLVE Chemistry's flagship offerings, such as its automated data collection system and advanced modeling capabilities, are integral to its revenue generation strategy, contributing to its standing within the industry as a provider of essential services to its clients. With the 2025 funding, SOLVE Chemistry aims to increase production capacity, expand its team, and develop additional capabilities for chemical manufacturers. The company plans to launch new products designed to further enhance their service offerings, although specific release dates are not mentioned. Additionally, SOLVE Chemistry is targeting expansion into North America and parts of Asia by the end of 2026, focusing on increasing its market presence in the pharmaceutical and agrochemical sectors.

## Funding rounds

- Seed, Jan 27, 2026, $5.4M — SuperSeed, XTX Ventures, Creator Fund, Endgame Capital

## Investors

- SuperSeed (https://capitalatlas.ai/funds/superseed) — Seed
- XTX Ventures (https://capitalatlas.ai/funds/xtx-ventures) — Seed
- Creator Fund (https://capitalatlas.ai/funds/creator-fund) — Seed
- Endgame Capital (https://capitalatlas.ai/funds/endgame-capital) — Seed